Sulfur Nonionically Bonded Patents (Class 514/562)
  • Patent number: 10335387
    Abstract: A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: July 2, 2019
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10111852
    Abstract: A method for treating bladder cancer including the steps of administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: October 30, 2018
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 10111843
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: October 30, 2018
    Assignees: Hough Ear Institute, Oklahoma Medical Research Foundation
    Inventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
  • Patent number: 10104882
    Abstract: Methods and compositions using 1,3-dicarbonyl compounds are disclosed for treating toxicity due to therapeutic agents and agents that causes oxidative cellular damage and for treating liver ischemia-reperfusion injury, as well as diseases and disorders that are improved through administration of N-acetylcysteine.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: October 23, 2018
    Assignee: Montefiore Medical Center
    Inventors: Richard M. LoPachin, Terrence Gavin
  • Patent number: 10092534
    Abstract: The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: October 9, 2018
    Assignee: BIOHIT OYJ
    Inventor: Osmo Suovaniemi
  • Patent number: 10080734
    Abstract: A method for treating autism and other neurodevelopmental disorders including the step of administering an effective amount of an isothiocyanate functional surfactant to a human, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant. The administration of the isothiocyanate functional surfactant may be augmented with a NMDA-receptor antagonist and/or a TNF-? inhibiting agent.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: September 25, 2018
    Assignee: The William M. Yarbrough foundation
    Inventor: Michael E. Silver
  • Patent number: 9988600
    Abstract: The present invention relates to cell culture media comprising polymer embedded components. Some components show poor stability in dry powder cell culture media. Others are hygroscopic. Such components can be embedded into polymers to increase stability and reduce clumping.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: June 5, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Michael Howard Rayner-Brandes, Joerg Von Hagen
  • Patent number: 9889103
    Abstract: The present application discloses an efficient process for the preparation of N-acetyl-L-cysteine amide (NACA) starting with N-acetyl-L-cysteine.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: February 13, 2018
    Assignee: NACUITY PHARMACEUTICALS, INC.
    Inventors: John C. Warner, Srinavasa Cheruku, Sambaiah Thota, John W. Lee
  • Patent number: 9849155
    Abstract: Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein comprising a compound of Formula (VI) wherein R1 and R2 are small peptides or modified peptides, are provided. The methods and compositions are useful in enhancing efficacy of drugs such as anti-inflammatory agents, neurological agents, thyroid agents, ocular agents, cancer chemotherapeutics, antibiotics, antimicrobials, antivirals and protease inhibitors to treat human immunodeficiency virus.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: December 26, 2017
    Inventors: Jeffrey D. Laskin, Ron Udasin, Lauren Aleksunes
  • Patent number: 9839621
    Abstract: A method for treating bladder cancer including the steps of administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: December 12, 2017
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 9840482
    Abstract: Provided herein are sulfonamide derivatives or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and use of such compounds or pharmaceutical compositions thereof for managing or treating 5-HT6 receptor-mediated diseases, especially in the manufacture of a medicament for managing or treating Alzheimer's disease.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: December 12, 2017
    Assignee: Sunshine Lake Pharma Co., Ltd.
    Inventors: Yingjun Zhang, Chuanfei Jin, Wenhe Zhong, Hongpeng Xie, Ji Zhang
  • Patent number: 9795582
    Abstract: A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: October 24, 2017
    Assignee: IASOMAI AB
    Inventors: Tiziana Parasassi, Graziella Costa, Ewa Krasnowska, Eugenia Pittaluga
  • Patent number: 9694030
    Abstract: The embodiments herein relate to a therapeutically active composition for the treatment, inhibition or attenuation of a virus. The composition comprises an effective amount of a sulfur containing compound along with one or more pharmaceutically acceptable carriers or excipients. The sulfur containing compound impairs a disulfide bond of a plurality of virus. The plurality of virus includes Ebola virus, herpes virus, dengue virus, smallpox virus, measles virus, mumps rubella virus, HIV (human immunodeficiency virus), Lassa fever virus and yellow fever virus, and even cancer, solid tumors, especially the fibrosarcoma tumor. The sulfur containing compound is sodium thiosulfate (Na2S2O3) (“STS”). The composition is given orally, intravenously, inhalation, intravesical, vaginal, rectal, sublingual, ophthalmic, or topical.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: July 4, 2017
    Inventor: Frederick J. Sawaya
  • Patent number: 9689841
    Abstract: UV-Absorbing and fluorescent pl markers for isoelectric focusing separations and fluorescent labeling, and methods for making and using the markers.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: June 27, 2017
    Assignee: The Texas A&M University System
    Inventors: Gyula Vigh, Ming-Chien Li
  • Patent number: 9650399
    Abstract: The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: May 16, 2017
    Assignees: The Governing Council of the University of Toronto, UTI Limited Partnership, Indiana University Research and Technology Corporation
    Inventors: Patrick Thomas Gunning, Sina Haftchenary, Brent David George Page, Samuel Weiss, Hema Artee Luchman, Melissa L. Fishel
  • Patent number: 9585854
    Abstract: The invention relates to a new use of NAC in IVF, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in IVF is proposed.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: March 7, 2017
    Assignee: IASOMAI AB
    Inventors: Thomas Lundeberg, Tiziana Parasassi, Eugenia Pittaluga, Roberto Brunelli
  • Patent number: 9561203
    Abstract: Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: February 7, 2017
    Inventors: William Brusilow, Paolo Bernardi
  • Patent number: 9546951
    Abstract: A reducing power analysis method for minimizing peak wavelength shift in a sample, comprising a reduction step of reducing a dye reagent containing a ferric compound and a cyanide at pH conditions of 2.4 or lower in the presence of a sample; and an optical measurement step of optically measuring a peak wavelength of a reduced form of the dye reagent obtained in the reduction step.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: January 17, 2017
    Assignee: ARKRAY, Inc.
    Inventor: Kazuhiro Ohmiya
  • Patent number: 9523671
    Abstract: The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to indoxyl sulfate as a biomarker in urine of the efficacy of prebiotics for the prevention of diet induced weight gain.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 20, 2016
    Assignee: NESTEC S.A.
    Inventors: Francois-Pierre Martin, Sebastiano Collino, Ivan Montoliu Roura
  • Patent number: 9456999
    Abstract: S-allylmercapto-N-acetylcysteine and related compounds are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compounds include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: October 4, 2016
    Assignee: Allium Vitalis, Inc.
    Inventor: David Michael Ott
  • Patent number: 9326960
    Abstract: Disclosed is a composition for preventing or treating eye diseases. The composition for preventing or treating eye diseases contains S-allyl-L-cysteine, a pharmaceutically acceptable salt thereof, or a solvate or a hydrate thereof as an active ingredient, and may inhibit photo-oxidation. The composition for preventing or treating eye diseases inhibits the accumulation of A2E in retinal pigment epithelial cells and the oxidation of A2E, thereby remarkably preventing or treating eye diseases including age-related macular degeneration or degenerative retinal disorder.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: May 3, 2016
    Assignee: PHARMAKING CO., LTD.
    Inventors: Soon Bae Kim, Gwang Soon Kim, Wan Bae Kim, Wie Jong Kwak, Sun Duck Jeon, Hyung Young Yoon, Young Pyo Jang
  • Patent number: 9249448
    Abstract: The invention pertains to the field of reaction systems generating malodor, particularly from constituents of human sweat. Specifically, the invention pertains to proteins for generating malodors, substrates for generating such malodor, inhibitors of such malodor generation and test and screening systems for measuring their malodor inhibition efficacy and finding substances previously not known to inhibit malodor generation. Thus, the invention also pertains to the field of deodorants.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: February 2, 2016
    Assignee: BASF SE
    Inventor: Markus Pompejus
  • Patent number: 9216163
    Abstract: A novel angiogenesis inhibitor, and a method for inhibiting angiogenesis are provided. Also provided are a prophylactic or therapeutic agent for a disease accompanied by angiogenesis, and a method for preventing or treating a disease accompanied by angiogenesis. The angiogenesis inhibitor contains L-carbocisteine or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: December 22, 2015
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Keizo Sato, Tomohiro Shinya, Shiori Nakayama
  • Patent number: 9155301
    Abstract: The invention relates to an antimicrobial agent where a cysteine compound is covalently bound to a substrate, in particular by binding through an S—S bridge via a spacer molecule to the substrate. The spacer comprises a carbon chain, optionally interrupted by one or more heteroatoms, e.g. O, S, N, P and Si; the chain is optionally substituted with one or more alkyl groups, preferably lower alkyl groups with 1-5 carbon atoms, hydroxyl groups or alkoxy groups. Also, the invention refers to a substrate that is coated with the antimicrobial agent of the invention. The agent has excellent antimicrobial properties and can be used to coat surfaces and substrates of various devices, such as medical devices or devices used in food handling, in order to prevent or inhibit accumulation and/or growth and/or proliferation and/or the viability of microorganisms and/or formation of biofilm.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: October 13, 2015
    Assignee: CYTACOAT AB
    Inventors: Anders Wirsen, Birgitta Agerberth, Gudmundur Gudmundsson, Jacob Odeberg, Torbjorn Lindberg
  • Patent number: 9139512
    Abstract: The degradation of an absorbent solution comprising organic compounds with an amine functional group in aqueous solution is substantially reduced in the presence of a small amount of degradation inhibiting agents belonging to the family of derivatives of triazoles or of a tetrazole at least one substituent of which contains a sulfur atom. The absorbent solution is used to deacidize a gaseous effluent.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: September 22, 2015
    Assignee: IFP ENERGIES NOUVELLES
    Inventors: P.-Louis Carrette, Bruno Delfort
  • Patent number: 9119821
    Abstract: Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: September 1, 2015
    Inventors: William Brusilow, Paolo Bernardi
  • Patent number: 9066914
    Abstract: An object of the present invention is to provide a prophylactic or ameliorating agent for pigmentation having a novel scaffold and an external preparation for skin containing the same as a component.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: June 30, 2015
    Assignee: POLA CHEMICAL INDUSTRIES INC.
    Inventors: Takashi Yamasaki, Yuko Saitoh, Chihiro Kondo
  • Publication number: 20150148395
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Applicant: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Publication number: 20150147309
    Abstract: The present invention relates to an allosteric non-inhibitory chaperone of the lysosomal acid alpha-glucosidase (GAA) for use in the treatment of a pathological condition characterized by a deficiency of the lysosomal acid alpha-glucosidase (GAA), to pharmaceutical composition thereof, to a method for increasing the activity of GAA in a subject and to a method for identifying an allosteric non-inhibitory chaperone for GAA.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 28, 2015
    Inventors: Giancarlo Parenti, Caterina Porto, Marco Moracci, Maria Carmina Ferrara, Beatrice Cobucci-Ponzano, Generoso Andria
  • Publication number: 20150147396
    Abstract: Nanoparticles are provided that comprise S-nitrosothiol (SNO) groups covalently bonded to the nanoparticles and/or S-nitrosothiol containing molecules encapsulated within the nanoparticles, as well as methods of making and using the nanoparticles. The invention also provides methods of preparing nanoparticles comprising Snitrosothiol (SNO) groups covalently bonded to the nanoparticles, where the methods comprise a) providing a buffer solution comprising chitosan, polyethylene glycol, nitrite, glucose, and hydrolyzed 3-mercaptopropyltrimethoxysilane (MPTS); b) adding hydrolyzed tetramethoxysilane (TMOS) to the buffer solution to produce a sol-gel; and c) lyophilizing and ball milling the sol-gel to produce nanoparticles of a desired size.
    Type: Application
    Filed: May 1, 2013
    Publication date: May 28, 2015
    Inventors: Parimala Nacharaju, Chaim Tuckman-Vernon, Adam J. Friedman, Pedro Cabrales, Joel M. Friedman
  • Publication number: 20150147411
    Abstract: The present invention relates to a composition for preventing or treating colitis. According to one embodiment of the present invention, the composition for preventing or treating colitis comprises S-allyl-L-cysteine, a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the same as an active ingredient, and exhibits an anti-inflammatory action in colitis. The composition for preventing or treating colitis has outstanding effects in preventing and alleviating colitis due to the effect of the anti-inflammatory action and the effect of an antioxidant action of S-allyl-L-cysteine, while at the same time S-allyl-L-cysteine is not accompanied by side-effects, therefore, has a wide scope of use against colitis.
    Type: Application
    Filed: July 3, 2013
    Publication date: May 28, 2015
    Applicant: PHARMAKING CO., LTD.
    Inventors: Soon Bae Kim, Gwang Soon Kim, Wan Bae Kim, Wie Jong Kwak, Sun Duck Jeon, Hyung Young Yoon, Ki Baik Hahm, Eun Hee Kim
  • Publication number: 20150140082
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 21, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Publication number: 20150141350
    Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.
    Type: Application
    Filed: September 4, 2014
    Publication date: May 21, 2015
    Inventors: Rangaramanujam M. Kannan, Sujatha Kannan, Roberto Romero, Raghavendra S. Navath, Hui Dai, Anupa R. Menjoge
  • Publication number: 20150141513
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological degenerative disorders and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of narcolepsy, shift work sleep disorder, and as an adjunct treatment for obstructive sleep apnea/hypopnea, hypersomnias, like idiopathic hypersomnia, Psychiatric/neurodegenerative disorders, ADHD, Psychiatric/neurodegenerative disorders, Depersonalization disorder, Cognitive enhancement, Fatigue, Post-chemotherapy cognitive impairment and weight loss.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 21, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150133470
    Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
  • Publication number: 20150132275
    Abstract: The present invention concerns a non-toxic solid pharmaceutical composition for oral administration, containing one or more cysteine compounds from the group of L-cysteine, D-cysteine and N-acetyl cysteine, combined with one or more additional active agents, at least one of which being selected from cystine, glutathione and methionine, the composition further containing one or more pharmaceutical additives. Further, the invention concerns a method for reducing the incidence of severe headaches, particularly migraine and/or cluster headaches.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 14, 2015
    Applicant: BIOHIT OYJ
    Inventor: Osmo Suovaniemi
  • Patent number: 9029385
    Abstract: The present invention relates, in general, to fibroproliferative disorders, and, in particular, to methods and compositions for treating fibroproliferative disorders by administering to a mammal in need of treatment pharmacologically effective doses of a phosphodiesterase inhibitor, such as pentoxifylline, and an anti-oxidant which is a precursor of glutathione, such as N-acetyl-cysteine, or their derivatives or metabolites.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: May 12, 2015
    Inventors: Ganesh Raghu, Douglas Harry Unwin, Lola Maksumova
  • Patent number: 9029322
    Abstract: The present invention relates to a method for identifying a drug candidate for enhancing expression of p21cip1/waf1 in a human patient suffering from a medical condition that can be treated by enhancing expression of p21C?1/waf1. The method includes (a) providing a cell line comprising a nucleic acid sequence that comprises a p21cip1/waf1 promoter operationally ligated to a reporter domain; (b) exposing the cell line to a compound; and (c) identifying a compound that induces expression of the reporter domain. The compound that induces expression of the reporter domain is a drug candidate for treating a medical condition that can be treated by enhancing expression of p21cip1/waf1.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: May 12, 2015
    Assignee: Cornell University
    Inventors: Rajiv R. Ratan, Brett C. Langley, Brian S. Ko
  • Publication number: 20150126571
    Abstract: Disclosed is a method comprising the administration of a 3% amino acid and 3% glycerin solution for the use of prevention and disruption of bacterial biofilms. Also disclosed is method comprising the administration of L-cysteine 0.4 g per 100 ml for the prevention and destruction of fungal biofilms.
    Type: Application
    Filed: January 6, 2015
    Publication date: May 7, 2015
    Inventor: THOMAS BENEDICT BRYAN
  • Publication number: 20150099806
    Abstract: A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: R1a—[O]v-(-A-L-)m-A-[O]v—R1b??I wherein A, L, R1a, R1b, m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.
    Type: Application
    Filed: December 14, 2014
    Publication date: April 9, 2015
    Inventors: Michael D. WARD, Zina ZHU
  • Publication number: 20150094276
    Abstract: This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).
    Type: Application
    Filed: April 19, 2013
    Publication date: April 2, 2015
    Inventor: Roger D. Tung
  • Patent number: 8993627
    Abstract: Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: March 31, 2015
    Assignee: Sentient LifeSciences, Inc.
    Inventor: Glenn A. Goldstein
  • Publication number: 20150087605
    Abstract: Disclosed are compositions and methods for treating anthrax, inhibiting anthrax toxins and inhibiting anthrax toxin-induced cytotoxicity. Carboxylic acid-containing small molecules can be used in the methods and compositions disclosed herein, for example, sulindac and derivatives thereof may be used. Methods of screening for carboxylic acid-containing small molecules that can be used to treat anthrax are disclosed. Targeting the anthrax toxin reduces the risks of anthrax spores.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 26, 2015
    Inventors: J. Manuel Perez Figueroa, Oscar Santiesteban, Charalambos Kaittanis
  • Patent number: 8987244
    Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) drug induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the h
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: March 24, 2015
    Assignee: PhilERA New Zealand Limited
    Inventors: Garth J. S. Cooper, John R. Baker
  • Publication number: 20150080468
    Abstract: Methionine products/additives are added to dairy cattle feeds to promote milk volume production and to enhance milk components. Unfortunately the methionine products/additives solidify/crystallize at about 54° F. (12° C.), making the products/additives difficult to dispense in a liquid storage and pumping system in cold conditions, thus requiring a time-consuming, expensive process using specialty equipment to de-crystallize the product. In one aspect this invention is an admixture that keeps the methionine products/additives temperature at a level that does not crystallize and thus, eliminates the expensive and time-consuming drawbacks to using methionine products in colder climates.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 19, 2015
    Applicant: QUALITY LIQUID FEEDS
    Inventors: Steve Freeman, Lisa Davis, Howard Blalock
  • Publication number: 20150072947
    Abstract: The present invention uses methylomic analysis and discovers DNA methylation biomarkers for prediction of ovarian cancer prognosis and detection of malignant ovarian cancer. In addition to being independent prognostic factors for patients with current treatment protocols, these DNA methylations are important biomarkers for individualized medicine for future chemotherapy (especially the demethylation agents or other epigenetic drugs).
    Type: Application
    Filed: August 30, 2012
    Publication date: March 12, 2015
    Applicant: National Defense Medical Center
    Inventors: Hung-Cheng Lai, Rui-Lan Huang
  • Publication number: 20150065534
    Abstract: The invention relates to compounds of formula (I), wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to LFA-1 integrin antagonists to target cells expressing LFA-1.
    Type: Application
    Filed: January 24, 2013
    Publication date: March 5, 2015
    Inventors: Robert Alan Goodnow, Jr., Matthew Michael Hamilton, Agnieszka Kowalczyk, Achyutharao Sidduri
  • Patent number: 8968791
    Abstract: The present invention provides a dietary supplement that promote the growth, repair, and maintenance of mammalian bone and joint connective tissue. In particular, the dietary supplement comprises a combination of at least one metal chelate and at least one chondroprotective agent.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: March 3, 2015
    Assignee: Novus International, Inc.
    Inventors: Jeremy D. Moore, Thomas R. Hampton, Robert Harrell
  • Publication number: 20150057237
    Abstract: The present invention relates to a modular supramolecular bioresorbable or biomedical material comprising (i) a polymer comprising at least two 4H-units and (ii) a biologically active compound. Optionally, the supramolecular bioresorbable or biomedical material comprises a bioresorbable or biomedical polymer as third component to tune its properties (mechanical and bioresorption properties). The supramolecular bioresorbable or biomedical material is especially suitable for biomedical applications such as controlled release of drugs, materials for tissue-engineering, materials for the manufacture of a prosthesis or an implant, medical imaging technologies.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 26, 2015
    Applicant: SupraPolix B.V.
    Inventors: Patricia Yvonne Wilhelmina DANKERS, Gaby Maria Leonarda HOORNE-VAN GEMERT, Henricus Marie JANSSEN, Egbert Willem MEIJER, Anton Willem BOSMAN
  • Publication number: 20150051259
    Abstract: Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease. Various pro-inflammatory mediators are elevated in a model of COPD that can be used predict the presence of COPD and/or subtypes of COPD in human patients. Profiles of these mediators can also predict the responsiveness of some patients to certain therapies, including thromboxane receptor antagonist treatment. Methods are provided for diagnosing a subject as a pulmonary disease candidate that include determining leukocyte expression in the subject of at least one pro-inflammatory mediator and identifying the subject as a pulmonary disease candidate when leukocyte expression in the subject of the pro-inflammatory mediator is increased compared to leukocyte expression of the pro-inflammatory mediator in a healthy individual. The pulmonary disease candidate can also be treated by administering a therapeutically effective amount of a thromboxane receptor antagonist.
    Type: Application
    Filed: April 9, 2013
    Publication date: February 19, 2015
    Inventors: John M. Hartney, Raul M. Torres, Roberta Pelanda